



ABIVAX to participate in the upcoming Jefferies Global Healthcare Conference in London and the German Equity Forum in Frankfurt

Paris, France November 12, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral and vaccine therapies for diseases like HIV/AIDS and the hepatitis B virus (HBV), today announced that its CEO, Prof. Dr. Hartmut Ehrlich will participate in the Jefferies 2015 Global Healthcare Conference in London on November 18 and 19, 2015.

Now in its sixth year, the Jefferies Global Healthcare Conference is the largest healthcare-dedicated conference in Europe. Last year, Jefferies had over 260 participating companies and 1,100 attendees and organized 2,100 business-to-business and investor meetings. At this year's conference, Dr. Ehrlich will meet in one-on-one meetings with institutional investors and leading pharmaceutical companies.

As announced previously, Prof. Ehrlich will also present at and participate in the German Equity Forum, to be held at the Sheraton Frankfurt Airport Hotel and Conference Center in Frankfurt on November 23 and 24, 2015. Prof. Ehrlich's presentation will take place on Monday, November 23rd at 3:30 PM, and he will meet with investors in one-on-one meetings over the course of both days.

ABIVAX's participation in the Jefferies 2015 Global Healthcare Conference and in the German Equity Forum kicks off the company's international investor relations strategy, which entails reaching out to a broader universe of global investors. This strategy includes sustained investor relations activities in the US, as well as in Europe.

ABIVAX (www.abivax.com) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.

Follow us on Twitter [@ABIVAX_](https://twitter.com/ABIVAX_)

Contacts

Prof. Hartmut J. Ehrlich, M.D., CEO of ABIVAX

Investor relations

Raquel Lizarraga
raquel.lizarraga@abivax.com
+33 1 53 83 06 93

Life Sci Advisors

Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press relations

ALIZE RP
Caroline Carmagnol and Florence Portejoie
abivax@alizerp.com
+33 6 64 18 99 59 / + 33 1 44 54 36 64